Bedrijfsoverzicht
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical entity dedicated to the discovery and development of therapeutic products designed to treat and prevent serious infectious diseases across both the United States and international markets. The company operates within the Healthcare sector, specifically focusing on the Biotechnology industry, a domain characterized by high research and development expenditures and significant regulatory scrutiny before products reach the market. As of the latest available data, the firm holds a market capitalization of $1.52 billion, generates annual revenue of $68.56 million, and employs a workforce of 367 individuals. The combination of a $1.52 billion market cap and revenue of $68.56 million suggests that the company possesses a substantial valuation relative to its current annual sales, which is typical for clinical-stage biotechnology firms where future pipeline potential is priced in rather than current profitability. This scale reflects the market's anticipation of the company's ability to successfully develop investigational therapies, particularly those targeting hepatitis, into approved products that could significantly alter its financial trajectory in the coming years.
Financiële gezondheid
Vir Biotechnology reported a revenue of $68.56 million over the trailing twelve months, yet it recorded a net income of -$437,987,008 and an EBITDA of -$456,340,000. The substantial disparity between the $68.56 million in revenue and the -$437,987,008 net income reveals a cost structure heavily weighted toward research, development, and operational expenses that far exceed current sales generation. The company's free cash flow stands at -$174,440,496, indicating a continuous outflow of capital that limits immediate financial flexibility and necessitates reliance on existing cash reserves or external financing to fund ongoing operations. Regarding profitability metrics, the gross margin is recorded at 0.0%, the operating margin at -74.9%, and the profit margin at 0.0%, collectively indicating that the company is currently operating at a loss at every stage of its financial hierarchy due to the capital-intensive nature of clinical-stage development. The balance sheet shows a cash position of $467.02 million against total debt of $97.85 million, resulting in a debt-to-equity ratio of 12.79, which highlights a leveraged capital structure where debt obligations are significant relative to shareholders' equity despite the company's non-dividend status. Liquidity is assessed via a current ratio of 5.54, which indicates a robust ability to meet short-term obligations as the company holds significantly more current assets than current liabilities. Furthermore, the return on equity is -45.7% and the return on assets is -24.4%, metrics that reveal that management is currently utilizing shareholder capital and assets to generate negative returns, a common phenomenon for early-stage biotechnology companies focused on pipeline advancement rather than immediate profit generation.
Waarderingsbeoordeling
The valuation metrics for Vir Biotechnology show a trailing P/E ratio of N/A and a forward P/E of -4.22, implying that the market is pricing the stock based on future earnings expectations rather than historical profitability, though the negative forward P/E reflects anticipated losses in the immediate future. The price-to-book ratio is 1.73, indicating that the market values the company at a premium of 73% over its tangible book value, which suggests investors are willing to pay extra for the intangible value of the intellectual property and clinical pipeline. Alternative valuation measures include a price-to-sales ratio of 22.15 and an EV/EBITDA of -2.10, suggesting that the stock is priced at more than twenty-two times its current sales, a multiple that emphasizes the potential future revenue upside from the therapeutic pipeline rather than current cash flows. The stock's trading range over the past year spans a 52-week high of $10.94 and a 52-week low of $4.16, placing the current price context within a wide band of volatility that is typical for biotechnology stocks sensitive to clinical trial outcomes. The beta value is 1.66, which indicates that the stock price is expected to be 66% more volatile than the broader market, meaning that during periods of market decline, VIR is likely to fall disproportionately more than the general index, while conversely, it may outperform during bullish market phases.
Growth & Income
The company's revenue growth year-over-year is an impressive 417.8%, while earnings growth is listed as N/A due to the absence of profitable operations to measure against prior periods. Since the earnings growth metric is unavailable because the company is not currently profitable, the revenue expansion of 417.8% represents the primary driver of scale, implying that the business model relies on top-line growth from new product approvals or licensing deals rather than immediate earnings improvement. As a non-dividend payer, Vir Biotechnology does not distribute cash to shareholders, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means the company retains all generated cash and any cash flow from operations to reinvest into its research and development pipeline. This strategy prioritizes funding clinical trials and asset acquisition over returning capital to investors, aligning with the standard operating model for clinical-stage biopharmaceutical companies that require significant capital to advance investigational therapies toward market approval. The overall growth and income profile is characterized by aggressive revenue expansion accompanied by significant negative earnings and cash flow, with no current income distribution to shareholders.